期刊： ANTIVIRAL THERAPY, 2023; 28 (6)
BackgroundPreviously, we have demonstrated that Apolipoprotein A-I (ApoA-I) could inhibit the secretion of Hepatitis B virus (HBV), suggesting that st......
期刊： ANTIVIRAL THERAPY, 2023; 28 (3)
BackgroundPimodivir is a first-in-class polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A polymerase complex. The randomized doubl......
期刊： ANTIVIRAL THERAPY, 2023; 28 (2)
Background: WHO guidelines recommend abacavir in first-line antiretroviral treatment for children and neonates. However, there is no approved dose <......
期刊： ANTIVIRAL THERAPY, 2023; 28 (3)
BackgroundTenofovir disoproxil fumarate is widely used in Botswana as part of the first-line antiretroviral regimen in the 'Treat All' strategy implem......
期刊： ANTIVIRAL THERAPY, 2023; 28 (5)
Contemporary antiretroviral therapy (ART) regimens have high barriers to the development of drug resistance. However, resistance to earlier antiretrov......
期刊： ANTIVIRAL THERAPY, 2023; 28 (4)
In endemic areas, hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfection is common, and patients with coinfection have a higher risk of developin......
期刊： ANTIVIRAL THERAPY, 2023; 28 (2)
Brainstem encephalitis is rare and this study aims to report the clinical course, imaging features, and therapeutic response of hiccup patient with ga......
期刊： ANTIVIRAL THERAPY, 2023; 28 (5)
Background: Avian infectious bronchitis virus (IBV), a coronavirus, causes a huge economic loss to the poultry industry. Andrographolide (APL) is a co......
期刊： ANTIVIRAL THERAPY, 2023; 28 (3)
BackgroundChronic hepatitis B (CHB) is responsible for major disease burden worldwide. However, the number of available therapies is limited; cure rem......
期刊： ANTIVIRAL THERAPY, 2023; 28 (3)
BackgroundPotential bidirectional drug-drug interactions between feminizing hormone therapy (FHT) and antiretroviral therapy (ART) are of concern for ......
期刊： ANTIVIRAL THERAPY, 2023; 28 (3)
Heavily treatment-experienced (HTE) persons with HIV have limited options for antiretroviral therapy and face many challenges, complicating their dise......
期刊： ANTIVIRAL THERAPY, 2023; 28 (5)
Background: Cytomegalovirus (CMV) infection is a frequent complication in haematopoietic cell/solid organ transplant (HCT/SOT) recipients. Previous st......
期刊： ANTIVIRAL THERAPY, 2023; 28 (1)
BackgroundJNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)-dependent mechanism, may enhance host immunity suppressed by persistent exp......
期刊： ANTIVIRAL THERAPY, 2023; 28 (2)
BackgroundCohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We ......
